Filing Details
- Accession Number:
- 0001140361-25-005660
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-02-24 16:05:16
- Reporting Period:
- 2025-02-20
- Filing Date:
- 2025-02-24
- Accepted Time:
- 2025-02-24 16:05:16
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 887359 | Vericel Corp | VCEL | Biological Products, (No Disgnostic Substances) (2836) | 943096597 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1801993 | C. Sean Flynn | 64 Sidney Street Cambridge MA 02139 | Chief Legal Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2025-02-20 | 3,835 | $57.32 | 756 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Acquisiton | 2025-02-20 | 35,000 | $0.00 | 35,000 | $54.31 |
| Common Stock | Restricted Stock Unit | Acquisiton | 2025-02-20 | 14,000 | $0.00 | 14,000 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 35,000 | 2035-02-20 | No | 4 | A | Direct | |
| 14,000 | No | 4 | A | Direct |
Footnotes
- The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2024.
- These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
- These options shall begin vesting on February 20, 2025 and shall continue to vest and become exercisable in equal quarterly installments over the course of the following four (4) year period.
- Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation.
- These RSUs vest in four annual installments with the initial vesting of RSUs granted to the Reporting Person on February 20, 2026. The remaining RSUs will vest in annual installments on February 20, 2027, February 20, 2028, and February 20, 2029, respectively.
- No expiration date for this type of award.
Billionaire Hedge Funds
